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[LETTER TO THE EDITOR
Neopterin and coronary artery disease
Dear Editor,
We read with great interest the article by
Zakynthinos and Pappa [1], who reviewed the
role of different markers of inﬂammation in coro-
nary artery disease (CAD), particularly C-reactive
protein (CRP). The review is exhaustive but unfor-
tunately the authors failed to mention neopterin,
a marker of macrophage activation [2—14].
Neopterin is a pteridine derivative and a byproduct
of the guanosine triphosphate—biopterin pathway
[3] that is produced by activated macrophages and
is thought to represent a marker of immune activa-
tion and macrophage activity [4].
Studies from our group [5—10] and others
[11—14] have shown that neopterin is a useful
marker of risk stratiﬁcation in patients with CAD.
We have previously shown a correlation between
neopterin levels and the presence of multiple
complex (vulnerable) plaques in patients with
unstable angina [6]. We also showed that increased
neopterin is a predictor of both worse outcome
in hypertensive patients with non-obstructive CAD
[7] and rapid CAD progression in patients with CAD
undergoing revascularization [9].
Grammer et al. [12] reported the predictive
value of neopterin in patients undergoing coro-
nary angiography and Vengen et al. expanded these
observations in patients with diabetes [13]. Of
interest, neopterin is a marker of cardiovascular
risk independently of the severity of CAD. Our pre-
vious work [5—10], recent data from van Haelst et
al. [11], Ray et al. [14], Grammer et al. [12] and
Vengen et al. [13] indicate that neopterin levels
identify a ‘‘vulnerable’’ phenotype among patients
with both stable CAD and acute coronary syndromes
[15,16].
There is growing evidence [17] for a role of
neopterin in patient cardiovascular risk stratiﬁ-
cation and we believe that neopterin deserves a
relevant place on the current list of markers of
inﬂammation and prognosis.
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uthor’s reply
ear Editor,We thank Dr Avanzas et al. for their interest
n our review study [1]. Our article commented
n the role of the most important inﬂammatory
iomarkers that are already applied in clinical prac-
s
t
o
i345
ice or are still under research, in coronary artery
isease (CAD). In fact, we have to apologize that
e did not report on all signiﬁcant markers that
ppear to provide prognostic information in individ-
als admitted for acute coronary syndromes (ACS),
ecause of the limitation of space. We mainly
ocused on C-reactive protein (CRP) and especially
igh-sensitivity CRP (hs-CRP) as these are the most
xtensively studied and until now considered to be
he most useful inﬂammatory markers for clinical
ractice in the setting of ACS.
Actually, besides cytokines, serum amyloid A,
dhesion molecules, myeloperoxidase, etc. that are
eported in our article, increased plasma levels
f cystatin C, ﬁbrinogen, ferritin, neopterin, and
erum levels of CD40-CD40L pathway seem to exert
mportant roles in progression, and outcome of
CS. Among them, neopterin deserved a notewor-
hy mention as increased neopterin plasma levels
eem to represent a signiﬁcant biomarker of inﬂam-
ation and plaque vulnerability, i.e. a marker of
AD activity, which is well associated with short-
nd long-term adverse cardiovascular outcomes
2—5].
Neopterin is released from human monocyte-
erived macrophages upon stimulation with
nterferon- and is a sensitive indicator for cel-
ular immune activation. In clinical evaluation
f patients, measurements of plasma levels of
eopterin are usually used to evaluate progression
f viral infections, renal transplant rejection,
evere systemic inﬂammatory diseases, nephritic
yndrome, and several autoimmune diseases [6—8].
lso patients with cardiovascular disease present
ith increased neopterin concentrations [9—10].
e agree with the comments of Dr Avanzas et al.
hat recent data further substantiate the predic-
ive information, which is provided by neopterin in
atients at risk of myocardial infarction and may be
strong indicator for risk stratiﬁcation in patients
ith CAD [2—5,11]. In addition, very recently
stevez-Loureiro et al. showed that neopterin
evels — but not CRP — showed a signiﬁcant inverse
orrelation with left ventricular ejection fraction;
igh neopterin concentrations were a predictor
f left ventricular dysfunction in patients with
hronic stable angina, irrespective of the extent
nd severity of CAD [12].
Therefore, we actually believe that, although
urther studies are necessary to elucidate the exact
ole of the biochemical markers in ACS, neopterin
eems to be clinically useful for risk stratiﬁcation in
hese patients and indeed deserves a precious place
n the current list of non-traditional biomarkers of
nﬂammation of atherosclerotic plaque.
